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Abstract
The objective of this study was to investigate the relationship of insulin-like
growth factor 2 (IGF2) expression and survival in women with uterine carcinosarcoma (UCS). Insulin-like growth factor 2 protein expression was determined
by immunohistochemical staining of tumor tissues from 103 patients with UCS.
The H-score (product of staining intensity and percentage positive cells) was
quantified for the epithelial cytoplasmic (EC), epithelial nuclear (EN), and malignant stromal compartments. Multivariable Cox proportional hazard regression
models were used to examine the relationship of IGF2 levels with progression-
free survival (PFS) and overall survival (OS). Adjusting for stage, race, and
adjuvant therapy, PFS and OS were reduced in patients with high IGF2 (H-score
≥ median) in the EC and EN compartments. Black race was independently
associated with reduced PFS and OS in patients with early-stage disease, and
IGF2 levels in the EC were higher in black than in white patients (P = 0.02,
Wilcoxon test). In a race-stratified multivariable analysis, high IGF2 in the epithelial compartments more than doubled the risk of death in black women;
HR = 2.43 (95% CI: 1.18–5.01, P = 0.02) for high IGF2 in the EC; and HR = 2.34
(95% CI: 1.25–4.39, P = 0.008) for high IGF2 in the EN. In conclusion, high
tumor IGF2 expression is an independent risk factor for reduced PFS and OS
in UCS. Black women have elevated tumor IGF2 compared with white women,
and decreased survival associated with high IGF2. These findings identify IGF2
as a candidate biomarker for survival linked to racial disparity in women with
UCS.

doi: 10.1002/cam4.1335

†These

authors contributed equally.

Introduction
Uterine carcinosarcoma (UCS) is a rare but highly aggressive uterine malignancy that accounts for a disproportionate
number of endometrial cancer deaths [1]. These biphasic
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tumors are composed of carcinomatous and sarcomatous
elements originating from a common progenitor cell [2].
Mutations in chromatin remodeling genes and histones
are implicated in the tumorigenesis of carcinosarcoma,
characterized by sarcomatous transformation of carcinoma
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cells via epithelial mesenchymal transition (EMT) [2–5].
Black women have more than a twofold higher incidence
of UCS compared to white women, as well as higher
mortality [6–8]. Five-year survival rates are approximately
30% for all women with UCS, and 50–60% for patients
with disease confined to the uterus [9].
The insulin-like growth factor 2 (IGF2) gene is located
on chromosome 11 and is one of the few hundred imprinted
genes in the genome. Imprinting is maintained by epigenetic
mechanisms, mainly DNA methylation [10]. IGF2 promotors are developmentally regulated and selectively repressed
in adult tissue types [11]. IGF2 upregulation has been
observed in many childhood and adult malignancies. IGF2
overexpression occurs in the majority of sarcomas, often
associated with loss of imprinting at the IGF2 locus, and
approximately 50% of uterine leiomyosarcomas have high
IGF2 expression [12]. Loss of IGF2 imprinting has also
been observed in UCS tumor tissue [13], and nonislet cell
hypoglycemia due to tumor production of incompletely
processed forms of pro-IGF2 (“big” IGF2) was previously
reported in patients with UCS [14], supporting a potential,
unrecognized role of IGF2 in UCS.
The insulin-
like growth factor (IGF) family includes
ligands (IGF1 and IGF2), tyrosine kinase receptors (IGF1R
and IGF2R), and IGF binding proteins. The interaction
between the ligands and the receptors is a complex, dynamic
interplay [10, 15]. IGF ligands as well as insulin bind to
IGF receptors, insulin receptors, and hybrid receptors,
leading to tyrosine autophosphorylation and activation.
Receptor activation leads to phosphorylation of insulin
receptor substrate and Src homology 2 domain-containing
transforming protein 1 (SHC). Phosphorylation of these
receptor substrates results in activation of the phosphatidylinositide 3-
kinase/AKT (PI3K/AKT) and mitogen-
activated protein kinase (MAPK) signaling cascades [16].
These signaling cascades inhibit apoptosis and promote
cellular proliferation. Reactivation of fetal IGF2 promoters
and IGF2 overexpression is associated with worse prognosis
in epithelial ovarian cancer and other cancers [17–19].
Dysregulation of the IGF signaling pathway is linked to
EMT, a major driver of metastasis and drug resistance
and a defining feature of UCS [15].
The objective of our study was to evaluate tumor IGF2
expression in a cohort of patients with UCS and determine
the relationship of IGF2 with clinicopathologic risk factors, and with disease progression and survival.

Methods
This study was reviewed and approved by the Institutional
Review Boards of the Albert Einstein College of Medicine
and the University of Alabama at Birmingham. Formalin-
fixed, paraffin-
embedded (FFPE) tumor specimens were
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retrieved from 103 uterine CS patients undergoing primary
surgical treatment.
Medical records were abstracted including date of
diagnosis, stage, age, race/ethnicity, body mass index in
kg/m2 (BMI), adjuvant therapy (chemotherapy, radiation
therapy, or both), disease recurrence or progression, and
date of death. Entry date for this analysis was defined as
the date of histopathological diagnosis. The date of death
was obtained by review of medical records and review
of the Social Security Death Index.

Immunohistochemistry
Immunohistochemistry was performed on FFPE tissue
sections (one case per glass slide) using a rabbit polyclonal antibody directed at the IGF2 ligand (AB9574;
Abcam Inc., Cambridge, MA). The optimized protocol
has been previously validated and described [17]. In brief,
Target Retrieval Solution, Citrate pH 6 (Dako North
America, Inc.) was used for antigen retrieval, TBS containing 5% goat serum and 2% bovine serum albumin
was used for blocking, and the primary antibody was
used at a 1:100 dilution with an incubation of 1 h at
room temperature. Secondary antibody and detection were
performed using the Dako Envision+ Polymer System
(Dako North America), followed by counterstaining with
hematoxylin. Staining of all tissue slides was performed
concurrently with staining of positive and negative control
sections.
Representative-stained carcinosarcoma tissue sections were
photographed on a Zeiss Axioskop II, and images shown
in Figure 1 depict the TIFF image files without modifications, other than cropping of the size. The study pathologist
(Y.W.), who was blinded to all clinical data, evaluated the
IGF2 staining intensity (0 negative, 1+ weak, 2+ moderate,
3+ strong) and the percentage of tumor cells with positive
staining (1–100%) in each tumor compartment (epithelial
cytoplasmic, epithelial nuclear, stromal cytoplasmic, and
stromal nuclear). IGF2 expression was summarized using
the H-score, which is defined as the product of the staining
intensity and the percentage of positive staining cells.

Statistical analysis
Patient demographics and clinical characteristics were
described as appropriate for continuous and categorical
variables. Standard descriptive statistics were used to
describe H-scores. H-scores were dichotomized at their
medians for each tumor compartment and categorized
as low IGF2 expression if the H-score was below the
compartment median or high IGF2 expression if the
H-score was equal to or above the compartment median.
Progression-free (PFS) and overall survival (OS) were
617
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Table 1. Demographic, pathologic, and treatment characteristics
(n = 103).
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Figure 1. IGF2 immunohistochemical staining in uterine carcinosarcoma.
Representative images of IGF2 immunohistochemistry are shown. In A
(4x obj.) and B (40x obj.), the uterine carcinosarcoma tissue shows low
IGF2 expression in all of the tumor compartments (EN, EC, SN, and SC).
In contrast, the UCS tissue shown in C and D had high IGF2 expression
in the EC and SC, but absent IGF2 expression in both nuclear
compartments (EN and SN). Positive and negative control tissue sections
are shown in E and F.

estimated using the Kaplan–Meier method and low-
versus high IGF2 expression was compared using the
log rank test. Univariable and multivariable Cox proportional hazard regression models were fit to examine
the relationship of demographic variables and IGF2
expression to PFS and OS. Variables with P < 0.10
in the univariable analysis were included in the multivariable model. All P-
values are two-
sided, and a
P-value of <0.05 was considered statistically significant.
All analyses were performed using Stata v13.0
(StataCorp, College Station, TX).

Results
Clinicopathologic characteristics of the 103 patients who
underwent primary surgical resection for uterine carcinosarcoma are shown in Table 1. Reflecting the known
epidemiological risk factors for carcinosarcoma, patients
were generally older, overweight or obese, and predominantly black.
Approximately half of patients had early stage (FIGO
Stage I or II) and half had advanced stage (FIGO Stage
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66.6 (11.2)
34.6 (10.4)
1 (1.0)
12 (11.7)
19 (18.4)
17 (16.5)
13 (12.6)
23 (22.3)
18 (17.5)
36 (35.0)

ϰϬп
;&Ϳ

;Ϳ

Age (years)*
BMI (kg/m2)*
BMI Categories
<18.5
18.5–24.9
25.0–29.9
30.0–34.9
35.0–39.9
≥40.0
Missing
Race/ethnicity
White

Black

66 (64.1)

Other
FIGO Stage
I

1 (0.9)
42 (40.8)

II

12 (11.6)

III

30 (29.1)

IV

19 (18.5)

Adjuvant therapy
No
47 (45.6)
Yes
56 (54.4)
Adjuvant chemotherapy
No
66 (64.1)
Yes
37 (35.9)
Adjuvant radiotherapy
No
83 (80.6)
Yes
20 (19.4)
Type of adjuvant RT
EBRT
9 (45.0)
EBRT +
7 (35.0)
brachy
therapy
Brachytherapy
3 (15.0)
only
Other
1 (5.0)
IGF2 H-scores†
Epithelial
65 [0–285]
nuclear
Epithelial
180 [60–300]
cytoplasmic
Stromal
60 [0–200]
nuclear
Stromal
160 [20–300]
cytoplasmic

Mesenchymal elements
Homologous
47 (45.6)
Heterologous
45 (43.7)
Missing
11 (10.7)
Residual tumor
No
82 (79.6)
Yes
20 (19.5)
N/A
1 (0.9)
*Reported as mean (standard deviation).
as median [Range].

†Reported

III or IV) UCS. Most patients received adjuvant therapy
following their surgery.
The median H-
score for IGF2 staining was higher in
the cytoplasmic compartment compared to the nuclear
compartment in both the malignant epithelial and malignant stromal tissue (Table 1). In less than 20% of cases,
either malignant epithelium or stroma was absent from
the stained section; therefore, missing H-scores by compartment were as follows: epithelial nuclear and cytoplasmic
n = 9, and stromal nuclear and cytoplasmic n = 10.
Representative images of IGF2 immunohistochemical staining are shown in Figure 1. Histograms depicting the H-score
distribution in each tissue component are shown in Figure
S1. As the H-
scores were not normally distributed, the
median values rather than the mean values were selected
as the optimal cutoff for defining high-versus low IGF2
expression. A moderate positive correlation was observed
between IGF2 EN and IGF2 SN (Spearman’s ρ = 0.65,
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Figure 2. IGF2 expression and progression-free survival (PFS). Kaplan–Meier curves depict the PFS in patients with high IGF2 expression (red line)
versus low IGF2 expression (blue line), measured in the following malignant tissue compartments: epithelial nuclear (A), epithelial cytoplasmic (B),
stromal nuclear (C), and stromal cytoplasmic (D). Patients with high-CS epithelial IGF2 expression had reduced PFS compared with patients with low
epithelial IGF2 expression (Log rank test P = 0.036 and P = 0.002 for epithelial nuclear and cytoplasmic compartments, respectively). Stromal IGF2
expression was not associated with PFS (Log rank test P = 0.79 and P = 0.91 for nuclear and cytoplasmic compartments, respectively).

P < 0.05), and between IGF2 EC and IGF2 SC (Spearman’s
ρ = 0.39, P < 0.05).

Progression-free survival
Over the course of follow-up (median 11.4 months), 75
patients had recurrence or progression of disease. The
median PFS was 10.3 months [IQ Range: 3.2–23.2 months].
Progression-free survival curves by tissue/cellular CS compartment are depicted in Figure 2. Patients with high-CS
epithelial IGF2 expression had reduced PFS compared
with patients with low epithelial IGF2 expression (Log
rank test P = 0.036 and P = 0.002 for epithelial nuclear
and cytoplasmic compartments, respectively). Malignant
stromal IGF2 expression was not associated with PFS (Log
rank test P = 0.79 and P = 0.91 for stromal nuclear and
cytoplasmic compartments, respectively).

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

The univariable and multivariable Cox proportional
hazard’s regression models for PFS are shown in Table 2.
In univariable regression, black race, higher stage, high
epithelial nuclear and cytoplasmic IGF2 expression were
associated with an increased hazard of disease progression.
Any adjuvant therapy was associated with a decreased
hazard of progression of disease. In the multivariable
model, after controlling for race, stage and adjuvant therapy
(specifically chemotherapy), high IGF2 expression in both
the epithelial nuclear and cytoplasmic compartments was
associated with roughly twice the hazard of progression
compared with low IGF2 expression (Epithelial nuclear
HR = 1.80, 95% CI: 1.08–2.99, P = 0.02 and epithelial
cytoplasmic HR = 2.07, 95% CI: 1.19–3.60, P = 0.01).
After adjustment for IGF2 and stage, neither race, nor
adjuvant therapy or chemotherapy, was independently
associated with PFS.
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Table 2. Univariable and multivariable Cox Proportional hazards models.
Progression-free survival

Variables
Age (years)
BMI (kg/m2)
Race
White
Black
FIGO Stage
I/II
III/IV
Sarcoma type
Homologous
Heterologous
Adjuvant therapy -any
No
Yes
Adjuvant chemotherapy
No
Yes
Adjuvant radiation
No
Yes
Epithelial nuclear IGF2
H-score < median (65)
H-score ≥ median (65)
Epithelial cytoplasmic IGF2
H-score < median (180)
H-score ≥ median (180)
Stromal nuclear IGF2
H-score < median (60)
H-score ≥ median (60)
Stromal cytoplasmic IGF2
H-score < median (160)
H-score ≥ median (160)

Univariable Hazard Ratio
(95% CI, P-value)

Overall survival
Multivariable Hazard
Ratio (95% CI, P-value)

1.01 (0.99–1.03, 0.60)
0.99 (0.97–1.02, 0.56)

Multivariable Hazard
Ratio (95% CI, P-value)

1.02 (0.99–1.04, 0.10)
0.98 (0.95–1.01, 0.22)

1.00 (reference)
1.79 (1.06–3.02, 0.03)

1.00 (reference)
1.68 (0.97–2.93, 0.07)

1.00 (reference)
1.78 (1.04–3.06, 0.04)

1.00 (reference)
1.68 (0.94–3.00, 0.08)

1.00 (reference)
2.27 (1.41–3.65, <0.01)

1.00 (reference)
2.11 (1.29–3.47, <0.01)

1.00 (reference)
2.25 (1.39–3.67, <0.01)

1.00 (reference)
2.28 (1.35–3.87, <0.01)

1.00 (reference)
1.10 (0.68–1.79, 0.70)

1.00 (reference)
0.95 (0.57–1.58, 0.84)

1.00 (reference)
0.59 (0.37–0.94, 0.03)

1.00 (reference)
0.55 (0.29–1.06, 0.07)

1.00 (reference)
0.50 (0.31–0.80, <0.01)

1.00 (reference)
0.40 (0.20–0.81, 0.01)

1.00 (reference)
0.64 (0.39–1.05, 0.08)

1.00 (reference)
1.15 (0.58–2.28, 0.70)

1.00 (reference)
0.59 (0.35–0.98, 0.04)

1.00 (reference)
1.15 (0.55–2.41, 0.71)

1.00 (reference)
0.83 (0.47–1.46, 0.51)

1.00 (reference)
0.67 (0.37–1.24, 0.20)

1.00 (reference)
1.64 (1.02–2.64, 0.04)

1.00 (reference)
1.80 (1.08–2.99, 0.02)

1.00 (reference)
1.72 (1.05–2.79, 0.03)

1.00 (reference)
1.86 (1.10–3.15, 0.02)

1.00 (reference)
2.17 (1.30–3.62, <0.01)

1.00 (reference)
2.07 (1.19–3.60, 0.01)

1.00 (reference)
2.11 (1.25–3.57, <0.01)

1.00 (reference)
1.98 (1.11–3.54, 0.02)

1.00 (reference)
1.07 (0.66–1.71, 0.79)

1.00 (reference)
1.04 (0.64–1.70, 0.86)

1.00 (reference)
1.03 (0.64–1.65, 0.91)

1.00 (reference)
1.07 (0.66–1.75, 0.76)

Overall survival
Seventy patients died of disease by the end of follow-up.
The median OS was 13.9 months [IQ range: 6.23–
51.9 months]. Overall survival curves by tissue/cellular
CS compartment are depicted in Figure 3. Similar to PFS,
OS was significantly lower in women with high-CS epithelial IGF2 expression (Log rank test P = 0.03 and
P = 0.005 for epithelial nuclear and cytoplasmic compartments, respectively). Malignant stromal IGF2 expression
was not associated with OS (Log rank test P = 0.86 and
P = 0.76 for stromal nuclear and cytoplasmic compartments, respectively).
The univariable and multivariable Cox proportional
hazard’s regression models for OS are shown in Table 2.
In univariable regression models, black race, higher stage,
and high epithelial nuclear and cytoplasmic IGF2 expression were associated with an increased risk of death. Any
adjuvant therapy was associated with a decreased risk of
620

Univariable Hazard Ratio
(95% CI, P-value)

death. In the multivariable model, after controlling for
race, stage and adjuvant therapy, high IGF2 expression
in both the epithelial nuclear and cytoplasmic compartments was associated with roughly twice the risk of death
compared with low IGF2 expression (Epithelial nuclear
HR = 1.86, 95% CI: 1.10–3.15, P = 0.02 and epithelial
cytoplasmic HR = 1.98, 95% CI: 1.11–3.54, P = 0.02).
Neither race nor adjuvant chemotherapy was independently
associated with OS, after adjustment for IGF2 and stage.

Stage and race
After stratifying patients by FIGO stage, high epithelial
cytoplasmic expression of IGF2 in early-stage UCS (stage
I/II) was associated with an increased risk of disease progression (HR = 2.18, 95% CI: 1.05–4.54, P = 0.04) and
death (HR = 3.41, 95% CI: 1.47–7.90, P < 0.01) after
adjusting for race and adjuvant therapy (Table 3).

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
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Figure 3. IGF2 expression and overall survival (OS). Kaplan–Meier curves depict the OS for patients with high IGF2 expression (red line) versus low
IGF2 expression (blue line), as measured in the following malignant tissue compartments: epithelial nuclear (A), epithelial cytoplasmic (B), stromal
nuclear (C), and stromal cytoplasmic (D). OS was significantly lower in women with high-CS epithelial IGF2 expression (Log rank test P = 0.03 and
P = 0.005 for epithelial nuclear and cytoplasmic compartments, respectively). Stromal IGF2 expression was not associated with OS (Log rank test
P = 0.86 and P = 0.76 for stromal nuclear and cytoplasmic compartments, respectively).

Additionally, in women with early-stage disease, black race
was an independent poor prognostic factor for progression
of disease (HR.2.83, 95% CI: 1.21–6.64, P = 0.02) and
death (HR = 2.80, 95% CI: 1.06–7.39; P = 0.04). In
patients with Stage III/IV disease, neither race nor IGF2
expression significantly impacted PFS or OS.
In FIGO stage I/II disease, IGF2 expression was higher
in the EC compartment of those with black race (Median
H-
score = 180, IQR: 160–190) compared to white race
(Median H-score = 160, IQR: 80–180), and this was significantly different (Wilcoxon Rank Sum test, P = 0.02).
Median H-scores did not differ between racial groups for
the other tissue/cellular compartments (EN, or either
stromal compartment).
After stratification of patients by race, high IGF2 in
the EC or the EN compartments was independently associated with worse survival in black women with UCS. A

© 2018 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

multivariable analysis was performed, including variables
with P < 0.1 on univariable analysis (Table S1). Adjusting
for stage and adjuvant therapy, the race-stratified HR for
black women was 2.43 (95% CI: 1.18–5.01, P = 0.02)
for high IGF2 in the EC, and the HR was 2.34 for high
IGF2 in the EN (95% CI: 1.25–4.39, P = 0.008), as shown
in Table 4.

Discussion
In this study, we found that elevated IGF2 protein expression is an independent poor prognostic factor in UCS.
For patients whose tumor epithelial compartment demonstrated IGF2 expression equal to or above the median
for the cohort, the risk of disease progression or death
was approximately doubled. We also found that black
women had higher tumor epithelial IGF2 expression

621

IGF2 and Race in Uterine Carcinosarcoma

A. R. Van Arsdale et al.

Table 3. Multivariable Cox proportional hazards models stratified by FIGO stage.
Stage I/II

Variables
Race
White
Black
Adjuvant therapy -any
No
Yes
Adjuvant chemotherapy
No
Yes
Epithelial Nuclear IGF2
H-score < median (65)
H-score ≥ median (65)
Epithelial Cytoplasmic IGF2
H-score < median (180)
H-score ≥ median (180)

Stage III/IV

PFS hazard ratio
(95% CI, P-value)

OS hazard ratio
(95% CI, P-value)

PFS hazard ratio
(95% CI, P-value)

OS hazard ratio
(95% CI, P-value)

1.00 (reference)
2.83 (1.21–6.64, 0.02)

1.00 (reference)
2.80 (1.06–7.39, 0.04)

1.00 (reference)
0.96 (0.42–2.18, 0.92)

1.00 (reference)
1.20 (0.53–2.74, 0.66)

1.00 (reference)
0.52 (0.19–1.43, 0.21)

1.00 (reference)
0.37 (0.12–1.19, 0.10)

1.00 (reference)
0.45 (0.17–1.20, 0.11)

1.00 (reference)
0.28 (0.10–0.76, 0.01)

1.00 (reference)
0.77 (0.25–2.36, 0.65)

1.00 (reference)
0.64 (0.18–2.32, 0.50)

1.00 (reference)
1.86 (0.73–4.74, 0.19)

1.00 (reference)
1.77 (0.66–4.74, 0.26)

1.00 (reference)
1.74 (0.78–3.86, 0.18)

1.00 (reference)
1.50 (0.64–3.53, 0.36)

1.00 (reference)
1.45 (0.69–3.03, 0.32)

1.00 (reference)
1.81 (0.84–3.90, 0.13)

1.00 (reference)
2.18 (1.05–4.54, 0.04)

1.00 (reference)
3.41 (1.47–7.90, <0.01)

1.00 (reference)
2.11 (0.88–5.07, 0.10)

1.00 (reference)
1.10 (0.48–2.52, 0.81)

Table 4. Cox stratified by race: Multivariable (keeping P < 0.10)
White
Variable
Stage
I/II
III/IV
Adjuvant therapy -Any
No
Yes
Epithelial Nuclear IGF2
H-Score <median (65)
H-Score >median (65)
Epithelial Cytoplasmic IGF2
H-Score <median (180)
H-Score >median (180)

Black

Hazard Ratio

95% CI

1.00 (ref.)
8.58

2.59–28.42

1.00 (ref.)
0.15

0.05–0.47

Hazard Ratio

95% CI

<0.001

1.00 (ref.)
1.95

1.04–3.66

1.00 (ref.)
0.48

0.27–0.87

1.00 (ref.)
2.34

1.25–4.39

1.00 (ref.)
2.43

1.18–5.01

0.001

compared to white women, and that high IGF2 was independently associated with worse survival in black women.
Conversely, the impact of race on PFS and OS was attenuated, and no longer significant, after adjustment for IGF2
and stage. These novel findings suggest that tumor epithelial
IGF2 expression is not only a prognostic biomarker in
UCS, but also that IGF2 expression differences may contribute to the racial disparity in disease outcome in patients
with UCS.
Unlike tumor epithelial IGF2 expression, the malignant
stromal IGF2 expression was not prognostic of disease
progression or survival. Recent studies of UCS show a
high level of clonality, favoring a metaplastic origin of
the sarcomatous elements derived from a common epithelial precursor as the carcinomatous elements [2, 5].
Interestingly, metastatic implants of UCS are composed
of purely carcinomatous elements in the majority of cases
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P-value

P-value
0.04

0.02

0.008

0.02

(69%), while 25% of cases have biphasic metastases and
only 4% of cases have purely sarcomatous metastases [20].
These observations support the primacy of the carcinomatous component as the driver of the UCS phenotype,
consistent with the findings of the present study.
The racial disparity in survival observed in this study
is consistent with a prior analysis of a clinical UCS cohort,
a subset of which comprises the IGF2 study cohort. As
previously reported in a retrospective review of 158 patients
treated for UCS at a single institution, outcomes were
worse in black women compared to white women with
early-stage disease after adjustment for adjuvant therapy
[7].
Uterine corpus cancer is among the cancers with the
largest racial disparity in survival. The five-year survival
rate is 86% in white women diagnosed with uterine cancer
compared with 66% in black women. In multiple other
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cancers, including prostate, breast, and colorectal cancer,
higher death rates are observed in blacks compared with
whites in the United States [21]. Socioeconomic status
and discrimination significantly contribute to racial disparity in cancer survival, including endometrial cancer
outcomes [22]. Aggressive histologic types of endometrial
cancer such as UCS occur more frequently in blacks,
implicating tumor biology as a contributing factor to differences in mortality rates [23].
As in endometrial cancer, the aggressive types of breast
cancer are more frequent in black women. A recent analysis
of The Cancer Genome Atlas (TCGA) breast cancer cohort
estimated that inherited germline variants account for 44%
of racial differences in breast cancer subtype distribution
[24]. Comparison of blacks and whites defined by genomically determined genetic ancestry identified not only differentially expressed genes and proteins, but also
significantly altered DNA methylation sites in breast cancer
tissue. However, an earlier study of endometrial cancers
from black and white women did not reveal significant
differences in gene transcription, but was limited by the
small number of patients [25]. Thus, nonbiological and
biological factors likely contribute to racial disparity in
uterine cancer survival.
While race is a social construct, self-
identified race
moderately correlates with genetic ancestry. It has been
reported that metabolic variables such as insulin resistance
preferentially cluster with genetic ancestry [26]. The tumor
necrosis factor (TNF)-α axis, a cytokine initiator of inflammation, shows differences in genotype and allele frequencies
(in TNF-
α and its receptor genes TNFR1 and TNFR2)
between blacks and whites [27]. Interestingly, TNF-α has
been identified as a regulator of IGF2 production by adipocytes [28].
Nonbiological factors may result in identifiable changes
in downstream biological mediators, wherein stress-
inducing conditions, nutrition, and environmental toxins
alter epigenetic markers and contribute to health disparities
[29]. For example, increasing poverty and nonwhite race
is associated with elevated C-reactive protein (CRP) levels
[30]. Of note, IGF2 is a regulator of CRP, and IGF2 was
among the first genes identified to be altered in expression as a result of fetal exposure to poor nutrition [31].
In addition, oxidative stress induces IGF2 overexpression
via loss of imprinting triggered by NF-κB activation [32].
IGF2 is one of a relatively small number of imprinted
genes in mammals, by which epigenetic silencing results
in monoallelic expression specific to parental origin [10].
Most imprinted genes have key functions during embryonic
development as is the case for IGF2. Upregulation of IGF2
occurs in both childhood and adult malignancies, and its
overexpression is linked to an aggressive phenotype of
ovarian and prostate cancer [17, 33]. Several important
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IGF2 regulatory mechanisms have been identified, many
of which overlap with functions during fetal development,
including altered transcription factor expression, epigenetic
changes such as altered DNA methylation, as well as
changes in post-
transcriptional and post-
translational
modulators of IGF2 expression [10].
Epigenetic events, particularly DNA methylation changes,
are triggered by environmental factors and are key drivers
of cancer development and progression [34]. Differences
in methylation status have been previously linked to racial
disparity in breast, prostate, colorectal, and endometrial
cancers [35]. The increased tumor expression of IGF2
observed in black women with UCS may reflect differences in DNA methylation at its regulatory sites. We
speculate that IGF2 expression is a potential biomarker
of prior environmental exposures and stressors as well as
heritable variations in metabolic and inflammatory pathways which interact to regulate IGF2 and cancer mortality
in UCS.
Our group has previously shown that increased tumor
expression of IGF2 in epithelial ovarian cancer cells is
associated with resistance to paclitaxel and other microtubule stabilizing drugs, and that IGF-
targeting therapy
restored drug sensitivity in cell line and xenograft models
of ovarian cancer [17, 36]. Other groups have shown that
IGF2 overexpression is associated with resistance to chemotherapy agents such as cisplatin, adriamycin, and fluorouracil [37–39]. As paclitaxel and platinum drugs comprise
the most commonly used adjuvant treatment for UCS,
modulation of chemosensitivity by IGF2 is highly clinically
relevant. Our laboratory is presently evaluating the ability
of IGF2-targeting therapy to enhance efficacy of chemotherapy using primary UCS cell lines and patient-derived
UCS xenografts.
In summary, we have identified IGF2 protein expression
as an independent poor prognostic biomarker in UCS, a
lethal uterine cancer that disproportionately impacts black
women. These novel findings, in conjunction with prior
studies of IGF2 in cancer, further substantiate that IGF2
is a biological mediator of an aggressive cancer phenotype
and a potential therapeutic target. Moreover, we have
uncovered a novel potential association of IGF2 with racial
disparity in UCS, which merits further investigation.
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